A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Crossref DOI link: https://doi.org/10.1007/s12094-015-1304-0
Published Online: 2015-06-02
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sepúlveda, J. M.
Belda-Iniesta, C.
Gil-Gil, M.
Pérez-Segura, P.
Berrocal, A.
Reynés, G.
Gallego, O.
Capellades, J.
Ordoñez, J. M.
La Orden, B.
Balañá, C.
Text and Data Mining valid from 2015-06-02